berberine has been researched along with Breast Cancer in 57 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| " Berberine, an extraordinary medicinal herb, has been proven to have many clinical pharmacological effects, including lowering of blood glucose, increasing insulin sensitivity, and correcting lipid metabolism disorders." | 8.98 | Relationship Between Metabolic Disorders and Breast Cancer Incidence and Outcomes. Is There a Preventive and Therapeutic Role for Berberine? ( Bonanni, B; Cazzaniga, M, 2018) |
| "Berberine plus baicalin intelligent micelles have excellent anti-tumor effects and no toxicity to normal tissues, which provides a new potential drug delivery strategy for the treatment of breast cancer." | 8.31 | Multiple stimulus-response berberine plus baicalin micelles with particle size-charge-release triple variable properties for breast cancer therapy. ( Chen, WW; Duan, XJ; Li, QQ; Li, QS; Li, XT; Li, XY; Qu, XW; Shi, LX; Shi, NN, 2023) |
| "Berberine exhibits anticancer efficacy against a variety of malignancies, including breast cancer (BRCA)." | 8.31 | Integrated network pharmacology, bioinformatics, and molecular docking to explore the mechanisms of berberine regulating autophagy in breast cancer. ( Huang, B; Li, R; Wen, G; Wu, M; Zou, Z, 2023) |
| "Berberine has shown anticancer properties and has potential for a chemopreventive and/or chemotherapeutic agent for breast cancer." | 7.91 | Berberine enhances posttranslational protein stability of p21/cip1 in breast cancer cells via down-regulation of Akt. ( Sabarwal, A; Shyanti, RK; Singh, RP; Tak, J, 2019) |
| " This study aimed to illustrate the effects of protoberberines on aryl hydrocarbon receptor (AhR) activation and cytochrome P450 (CYP) 1 in the estrogen receptor (ER)α(+) MCF-7 breast cancer cells." | 7.85 | Berberine Activates Aryl Hydrocarbon Receptor but Suppresses CYP1A1 Induction through miR-21-3p Stimulation in MCF-7 Breast Cancer Cells. ( Chen, YS; Huang, CC; Lee, IJ; Li, LA; Lo, SN; Ueng, YF; Wang, CW; Wu, TS, 2017) |
| "Lapatinib, a novel tyrosine kinase inhibitor of HER2/EGFR, is used to treat HER2-positive breast cancer." | 7.83 | Berberine reverses lapatinib resistance of HER2-positive breast cancer cells by increasing the level of ROS. ( Chen, S; Chen, X; Dou, K; Qiao, H; Wei, L; Zhang, J; Zhang, R, 2016) |
| "Berberine is a plant-derived compound used in traditional Chinese medicine, which has been shown to inhibit cell proliferation and migration in breast cancer." | 7.83 | Tumor suppressor berberine binds VASP to inhibit cell migration in basal-like breast cancer. ( Hu, P; Kuang, C; Su, K; Wang, X; Wei, L; Xiang, J; Xiang, Q; Yang, F; Zhang, J; Zhu, S, 2016) |
| "Effects of coptisine on highly metastatic human breast cancer cell MDA-MB-231 proliferation were evaluated by trypan blue assay and on cell adhesion, migration and invasion by gelatin adhesion, wound-healing and matrigel invasion chamber assays, respectively." | 7.80 | Suppression of human breast cancer cell metastasis by coptisine in vitro. ( Cao, SP; Chen, SH; Li, J; Qiu, DM; Xia, XL, 2014) |
| " Herein, we investigated how cell invasion was regulated by berberine (BBR), an isoquinoline derivative alkaloid compound, in MDA-MB-231 human breast cancer cells." | 7.74 | Berberine suppresses TNF-alpha-induced MMP-9 and cell invasion through inhibition of AP-1 activity in MDA-MB-231 human breast cancer cells. ( Choi, JH; Kim, JB; Kim, JH; Kim, S; Lee, JE; Nam, SJ; Yang, JH, 2008) |
| "Breast cancer is one of the main challenging areas in cancer treatment." | 5.62 | Evaluation of the Effects of Nanomicellar Curcumin, Berberine, and Their Combination with 5-Fluorouracil on Breast Cancer Cells. ( Ghasemi, F; Sahebkar, A; Ziasarabi, P, 2021) |
| "Elevated SIK3 expressions in breast cancer cells are shown to contribute to tumorigenesis; however, the underlying mechanism remains to be elucidated." | 5.56 | Berberine and Emodin abrogates breast cancer growth and facilitates apoptosis through inactivation of SIK3-induced mTOR and Akt signaling pathway. ( Kothandan, G; Manoharan, R; Ponnusamy, L, 2020) |
| "Breast cancer is the most common reason of cancer death in women." | 5.56 | In-vitro and in-vivo anti-breast cancer activity of synergistic effect of berberine and exercise through promoting the apoptosis and immunomodulatory effects. ( Li, X; Ma, W; Wang, B; Xu, S; Ye, X; Yu, M; Zhang, J; Zhang, Y, 2020) |
| "Berberine (BBR) is a natural isoquinoline alkaloid, which is used in traditional medicine for its anti-microbial, anti-protozoal, anti-diarrhoeal activities." | 5.51 | Berberine attenuates XRCC1-mediated base excision repair and sensitizes breast cancer cells to the chemotherapeutic drugs. ( Gao, X; Ji, J; Li, M; Lv, J; Mao, W; Sun, C; Wang, J; Yang, W; Zhang, L; Zhao, Z, 2019) |
| "BACKGROUND Breast cancer is a common malignant tumor worldwide." | 5.51 | Berberine Inhibits Proliferative Ability of Breast Cancer Cells by Reducing Metadherin. ( Sun, Y; Tong, Y; Wang, W, 2019) |
| "Berberine is an alkaloid plant-based DNA intercalator that affects gene regulation, particularly expression of oncogenic and tumor suppressor proteins." | 5.51 | Antitumor effects of berberine against EGFR, ERK1/2, P38 and AKT in MDA-MB231 and MCF-7 breast cancer cells using molecular modelling and in vitro study. ( Ismail, P; Jabbarzadeh Kaboli, P; Leong, MP; Ling, KH, 2019) |
| "Breast cancer is the most common type of cancer and the second leading cause of cancer death in American women." | 5.46 | Berberine Reverses Hypoxia-induced Chemoresistance in Breast Cancer through the Inhibition of AMPK- HIF-1α. ( Chen, L; He, K; Li, J; Pan, Y; Shao, D; Tan, Y; Zhang, F; Zhao, Y; Zheng, X, 2017) |
| "Berberine was isolated from C." | 5.46 | Berberine inhibits the proliferation and migration of breast cancer ZR-75-30 cells by targeting Ephrin-B2. ( Li, X; Ma, W; Yang, L; Yang, T; Zhang, D; Zhang, Y; Zhu, M, 2017) |
| " The aim of the present study was to investigate the effects of BBR in combination with cisplatin on human breast cancer cells." | 5.43 | Berberine in combination with cisplatin suppresses breast cancer cell growth through induction of DNA breaks and caspase-3-dependent apoptosis. ( Jing, Z; Li, Y; Mao, W; Zhao, Y, 2016) |
| "Treatment of human breast cancer cells (MCF-7 and MDA-MB-231 cells) with berberine induced inhibition of cell viability in concentration- and time-dependent manner irrespective of their estrogen receptor (ER) expression." | 5.42 | Berberine-induced apoptosis in human breast cancer cells is mediated by reactive oxygen species generation and mitochondrial-related apoptotic pathway. ( Chen, Y; Fu, J; Huang, X; Wang, L; Xi, M; Xie, J; Xu, Y, 2015) |
| "The recurrence of breast cancer is associated with drug-resistance of cancer stem cells (CSCs), while overexpression of cell membrane ATP-binding cassette (ABC) transporters and resistance of mitochondrial apoptosis-related proteins are responsible for the drug-resistance of CSCs." | 5.39 | Modulation of drug-resistant membrane and apoptosis proteins of breast cancer stem cells by targeting berberine liposomes. ( Ju, RJ; Li, N; Li, XY; Lu, WL; Ma, X; Mu, LM; Shi, JF; Sun, MG; Yan, Y; Zhang, CX; Zhao, WY; Zhou, J, 2013) |
| "Berberine (BBR) is an isoquinoline alkaloid and is beneficial for the anticancer effect on a variety of human tumor cells." | 5.39 | Berberine suppresses TPA-induced fibronectin expression through the inhibition of VEGF secretion in breast cancer cells. ( Bae, SY; Gil, WH; Han, J; Jeon, M; Jung, T; Kim, J; Kim, S; Kim, SW; Lee, J; Lee, JE; Lee, SK; Nam, SJ; Oh, SJ, 2013) |
| "Berberine (BBR) is a natural alkaloid with significant antitumor activities against many types of cancer cells." | 5.38 | Berberine, an isoquinoline alkaloid, inhibits the metastatic potential of breast cancer cells via Akt pathway modulation. ( Chen, YC; Chuang, TC; Hsu, SC; Kao, MC; Kuo, CL; Kuo, HP; Kuo, YH; Liu, JY; Tsai, SC; Tseng, HH, 2012) |
| "Berberine is a natural product isolated from herbal plants such as Rhizoma coptidis which has been shown to have anti-neoplastic properties." | 5.38 | Proteomic and redox-proteomic analysis of berberine-induced cytotoxicity in breast cancer cells. ( Chan, HL; Chen, YW; Cheng, CS; Chou, HC; Lin, CW; Lu, YC; Lyu, PC; Timms, JF, 2012) |
| "Berberine pre-treatment prolonged the persistence of DNA double-strand breaks in the MCF-7 cell line." | 5.38 | Radiosensitization effects of berberine on human breast cancer cells. ( Liu, Q; Wang, J; Yang, Q, 2012) |
| "Berberine (BBR) is a natural alkaloid with significant antitumor activities against many types of cancer cells." | 5.37 | Growth suppression of HER2-overexpressing breast cancer cells by berberine via modulation of the HER2/PI3K/Akt signaling pathway. ( Chang, YH; Chen, PY; Chuang, TC; Hsu, SC; Kao, MC; Kuo, HP; Liu, JY; Wang, SS; Way, TD; Yeh, MH, 2011) |
| "Treatment with berberine-induced cell cycle arrest at G0/G1 in the anoikis-resistant MCF-7 and MDA-MB-231 cells as compared to untreated control cells." | 5.36 | The alkaloid Berberine inhibits the growth of Anoikis-resistant MCF-7 and MDA-MB-231 breast cancer cell lines by inducing cell cycle arrest. ( Han, W; Kim, JB; Ko, E; Lee, KW; Noh, DY; Park, SY; Shin, I; Song, AK; Yu, JH, 2010) |
| "Berberine was added to MCF-7 cells in culture, and proliferation, side population (SP) cells and expression of ABCG2 were examined." | 5.35 | Berberine diminishes the side population and ABCG2 transporter expression in MCF-7 breast cancer cells. ( Han, W; Kim, JB; Ko, E; Noh, DY; Park, SY; Shin, I, 2008) |
| "Berberine was added to proliferating MCF-7 and MDA-MB-231 cells in culture." | 5.35 | Berberine inhibits growth of the breast cancer cell lines MCF-7 and MDA-MB-231. ( Bae, JY; Han, W; Kim, JB; Kim, S; Ko, E; Lee, JE; Lee, KM; Noh, DY; Shin, I, 2008) |
| " Berberine, an extraordinary medicinal herb, has been proven to have many clinical pharmacological effects, including lowering of blood glucose, increasing insulin sensitivity, and correcting lipid metabolism disorders." | 4.98 | Relationship Between Metabolic Disorders and Breast Cancer Incidence and Outcomes. Is There a Preventive and Therapeutic Role for Berberine? ( Bonanni, B; Cazzaniga, M, 2018) |
| "Berberine plus baicalin intelligent micelles have excellent anti-tumor effects and no toxicity to normal tissues, which provides a new potential drug delivery strategy for the treatment of breast cancer." | 4.31 | Multiple stimulus-response berberine plus baicalin micelles with particle size-charge-release triple variable properties for breast cancer therapy. ( Chen, WW; Duan, XJ; Li, QQ; Li, QS; Li, XT; Li, XY; Qu, XW; Shi, LX; Shi, NN, 2023) |
| "Berberine exhibits anticancer efficacy against a variety of malignancies, including breast cancer (BRCA)." | 4.31 | Integrated network pharmacology, bioinformatics, and molecular docking to explore the mechanisms of berberine regulating autophagy in breast cancer. ( Huang, B; Li, R; Wen, G; Wu, M; Zou, Z, 2023) |
| "Berberine alkaloids belong to the class of isoquinoline alkaloids that have been shown to possess anticancer potential, berberine exhibits inhibitory effects on breast cancer development." | 4.12 | Berberine alkaloids inhibit the proliferation and metastasis of breast carcinoma cells involving Wnt/β-catenin signaling and EMT. ( Dian, L; Drobot, L; Horak, I; Li, J; Lu, H; Sun, Y; Wang, J; Xu, Z; Zheng, M, 2022) |
| " Berberine is an isoquinoline plant alkaloid with remarkable antioxidant and anti-inflammation roles, which is used in ethnic medicines, including traditional Chinese and North American medicine." | 3.96 | Berberine Inhibits MDA-MB-231 Cells by Attenuating Their Inflammatory Responses. ( Zhang, C; Zhao, L, 2020) |
| "Berberine has shown anticancer properties and has potential for a chemopreventive and/or chemotherapeutic agent for breast cancer." | 3.91 | Berberine enhances posttranslational protein stability of p21/cip1 in breast cancer cells via down-regulation of Akt. ( Sabarwal, A; Shyanti, RK; Singh, RP; Tak, J, 2019) |
| " This study aimed to illustrate the effects of protoberberines on aryl hydrocarbon receptor (AhR) activation and cytochrome P450 (CYP) 1 in the estrogen receptor (ER)α(+) MCF-7 breast cancer cells." | 3.85 | Berberine Activates Aryl Hydrocarbon Receptor but Suppresses CYP1A1 Induction through miR-21-3p Stimulation in MCF-7 Breast Cancer Cells. ( Chen, YS; Huang, CC; Lee, IJ; Li, LA; Lo, SN; Ueng, YF; Wang, CW; Wu, TS, 2017) |
| "Lapatinib, a novel tyrosine kinase inhibitor of HER2/EGFR, is used to treat HER2-positive breast cancer." | 3.83 | Berberine reverses lapatinib resistance of HER2-positive breast cancer cells by increasing the level of ROS. ( Chen, S; Chen, X; Dou, K; Qiao, H; Wei, L; Zhang, J; Zhang, R, 2016) |
| "Berberine is a plant-derived compound used in traditional Chinese medicine, which has been shown to inhibit cell proliferation and migration in breast cancer." | 3.83 | Tumor suppressor berberine binds VASP to inhibit cell migration in basal-like breast cancer. ( Hu, P; Kuang, C; Su, K; Wang, X; Wei, L; Xiang, J; Xiang, Q; Yang, F; Zhang, J; Zhu, S, 2016) |
| "Effects of coptisine on highly metastatic human breast cancer cell MDA-MB-231 proliferation were evaluated by trypan blue assay and on cell adhesion, migration and invasion by gelatin adhesion, wound-healing and matrigel invasion chamber assays, respectively." | 3.80 | Suppression of human breast cancer cell metastasis by coptisine in vitro. ( Cao, SP; Chen, SH; Li, J; Qiu, DM; Xia, XL, 2014) |
| "The aim of this paper was to determine the activity of a natural nutraceuticals combination (AP=Berberine+Red Yeast Rice) on dyslipidemia which frequently persists after life style changes in patients on hormone-therapy following breast cancer (HT-BC)." | 3.78 | Use of a lipid-lowering food supplement in patients on hormone therapy following breast cancer. ( Benvenuti, C; Pezzana, A; Quirico, E; Zanardi, M, 2012) |
| " Herein, we investigated how cell invasion was regulated by berberine (BBR), an isoquinoline derivative alkaloid compound, in MDA-MB-231 human breast cancer cells." | 3.74 | Berberine suppresses TNF-alpha-induced MMP-9 and cell invasion through inhibition of AP-1 activity in MDA-MB-231 human breast cancer cells. ( Choi, JH; Kim, JB; Kim, JH; Kim, S; Lee, JE; Nam, SJ; Yang, JH, 2008) |
| " Berberine as well as lovastatin, an inhibitor of the mevalonate pathway, exerted dose-dependent cytostatic/cytotoxic effects against human breast cancer cells (MDA-MB231)." | 3.73 | Berberine, a natural cholesterol reducing product, exerts antitumor cytostatic/cytotoxic effects independently from the mevalonate pathway. ( Golab, J; Issat, T; Jakóbisiak, M, 2006) |
| "KRas is frequently mutated in pancreatic cancers." | 1.62 | GSK-3β Can Regulate the Sensitivity of MIA-PaCa-2 Pancreatic and MCF-7 Breast Cancer Cells to Chemotherapeutic Drugs, Targeted Therapeutics and Nutraceuticals. ( Abrams, SL; Akula, SM; Candido, S; Cervello, M; Cocco, L; Duda, P; Falzone, L; Gizak, A; Libra, M; Martelli, AM; McCubrey, JA; Meher, AK; Montalto, G; Rakus, D; Ratti, S; Ruvolo, P; Steelman, LS, 2021) |
| "Breast cancer is one of the main challenging areas in cancer treatment." | 1.62 | Evaluation of the Effects of Nanomicellar Curcumin, Berberine, and Their Combination with 5-Fluorouracil on Breast Cancer Cells. ( Ghasemi, F; Sahebkar, A; Ziasarabi, P, 2021) |
| "Breast cancer is the most common reason of cancer death in women." | 1.56 | In-vitro and in-vivo anti-breast cancer activity of synergistic effect of berberine and exercise through promoting the apoptosis and immunomodulatory effects. ( Li, X; Ma, W; Wang, B; Xu, S; Ye, X; Yu, M; Zhang, J; Zhang, Y, 2020) |
| "Elevated SIK3 expressions in breast cancer cells are shown to contribute to tumorigenesis; however, the underlying mechanism remains to be elucidated." | 1.56 | Berberine and Emodin abrogates breast cancer growth and facilitates apoptosis through inactivation of SIK3-induced mTOR and Akt signaling pathway. ( Kothandan, G; Manoharan, R; Ponnusamy, L, 2020) |
| "BACKGROUND Breast cancer is a common malignant tumor worldwide." | 1.51 | Berberine Inhibits Proliferative Ability of Breast Cancer Cells by Reducing Metadherin. ( Sun, Y; Tong, Y; Wang, W, 2019) |
| "Berberine is an alkaloid plant-based DNA intercalator that affects gene regulation, particularly expression of oncogenic and tumor suppressor proteins." | 1.51 | Antitumor effects of berberine against EGFR, ERK1/2, P38 and AKT in MDA-MB231 and MCF-7 breast cancer cells using molecular modelling and in vitro study. ( Ismail, P; Jabbarzadeh Kaboli, P; Leong, MP; Ling, KH, 2019) |
| "Berberine (BBR) is a natural isoquinoline alkaloid, which is used in traditional medicine for its anti-microbial, anti-protozoal, anti-diarrhoeal activities." | 1.51 | Berberine attenuates XRCC1-mediated base excision repair and sensitizes breast cancer cells to the chemotherapeutic drugs. ( Gao, X; Ji, J; Li, M; Lv, J; Mao, W; Sun, C; Wang, J; Yang, W; Zhang, L; Zhao, Z, 2019) |
| "Berberine was isolated from C." | 1.46 | Berberine inhibits the proliferation and migration of breast cancer ZR-75-30 cells by targeting Ephrin-B2. ( Li, X; Ma, W; Yang, L; Yang, T; Zhang, D; Zhang, Y; Zhu, M, 2017) |
| "Breast cancer is the most common type of cancer and the second leading cause of cancer death in American women." | 1.46 | Berberine Reverses Hypoxia-induced Chemoresistance in Breast Cancer through the Inhibition of AMPK- HIF-1α. ( Chen, L; He, K; Li, J; Pan, Y; Shao, D; Tan, Y; Zhang, F; Zhao, Y; Zheng, X, 2017) |
| " The aim of the present study was to investigate the effects of BBR in combination with cisplatin on human breast cancer cells." | 1.43 | Berberine in combination with cisplatin suppresses breast cancer cell growth through induction of DNA breaks and caspase-3-dependent apoptosis. ( Jing, Z; Li, Y; Mao, W; Zhao, Y, 2016) |
| "Berberine (BBR) is a natural isoquinoline alkaloid with proven antiangiogenic and anticancer activities." | 1.42 | Antiangiogenic and antitumor activities of berberine derivative NAX014 compound in a transgenic murine model of HER2/neu-positive mammary carcinoma. ( Bartozzi, B; Damiani, E; Donati, A; Geroni, C; Lombardi, P; Lucarini, G; Orlando, F; Pierpaoli, E; Provinciali, M; Salvatore, C, 2015) |
| "Treatment of human breast cancer cells (MCF-7 and MDA-MB-231 cells) with berberine induced inhibition of cell viability in concentration- and time-dependent manner irrespective of their estrogen receptor (ER) expression." | 1.42 | Berberine-induced apoptosis in human breast cancer cells is mediated by reactive oxygen species generation and mitochondrial-related apoptotic pathway. ( Chen, Y; Fu, J; Huang, X; Wang, L; Xi, M; Xie, J; Xu, Y, 2015) |
| "Berberine (BBR) is an isoquinoline alkaloid and is beneficial for the anticancer effect on a variety of human tumor cells." | 1.39 | Berberine suppresses TPA-induced fibronectin expression through the inhibition of VEGF secretion in breast cancer cells. ( Bae, SY; Gil, WH; Han, J; Jeon, M; Jung, T; Kim, J; Kim, S; Kim, SW; Lee, J; Lee, JE; Lee, SK; Nam, SJ; Oh, SJ, 2013) |
| "The recurrence of breast cancer is associated with drug-resistance of cancer stem cells (CSCs), while overexpression of cell membrane ATP-binding cassette (ABC) transporters and resistance of mitochondrial apoptosis-related proteins are responsible for the drug-resistance of CSCs." | 1.39 | Modulation of drug-resistant membrane and apoptosis proteins of breast cancer stem cells by targeting berberine liposomes. ( Ju, RJ; Li, N; Li, XY; Lu, WL; Ma, X; Mu, LM; Shi, JF; Sun, MG; Yan, Y; Zhang, CX; Zhao, WY; Zhou, J, 2013) |
| "Berberine is an isoquinoline alkaloid that has several pharmacological effects such as antiinflammatory, antimicrobial, apoptosis-inducing and anticancer effects." | 1.38 | COX-2 and survivin reduction may play a role in berberine-induced apoptosis in human ductal breast epithelial tumor cell line. ( Ahmadian, S; Javadifar, N; Pazhang, Y; Shafiezadeh, M, 2012) |
| "Berberine is a natural product isolated from herbal plants such as Rhizoma coptidis which has been shown to have anti-neoplastic properties." | 1.38 | Proteomic and redox-proteomic analysis of berberine-induced cytotoxicity in breast cancer cells. ( Chan, HL; Chen, YW; Cheng, CS; Chou, HC; Lin, CW; Lu, YC; Lyu, PC; Timms, JF, 2012) |
| "Berberine pre-treatment prolonged the persistence of DNA double-strand breaks in the MCF-7 cell line." | 1.38 | Radiosensitization effects of berberine on human breast cancer cells. ( Liu, Q; Wang, J; Yang, Q, 2012) |
| "Berberine (BBR) is a natural alkaloid with significant antitumor activities against many types of cancer cells." | 1.38 | Berberine, an isoquinoline alkaloid, inhibits the metastatic potential of breast cancer cells via Akt pathway modulation. ( Chen, YC; Chuang, TC; Hsu, SC; Kao, MC; Kuo, CL; Kuo, HP; Kuo, YH; Liu, JY; Tsai, SC; Tseng, HH, 2012) |
| "Berberine (BBR) is a natural alkaloid with significant antitumor activities against many types of cancer cells." | 1.37 | Growth suppression of HER2-overexpressing breast cancer cells by berberine via modulation of the HER2/PI3K/Akt signaling pathway. ( Chang, YH; Chen, PY; Chuang, TC; Hsu, SC; Kao, MC; Kuo, HP; Liu, JY; Wang, SS; Way, TD; Yeh, MH, 2011) |
| "Treatment with berberine-induced cell cycle arrest at G0/G1 in the anoikis-resistant MCF-7 and MDA-MB-231 cells as compared to untreated control cells." | 1.36 | The alkaloid Berberine inhibits the growth of Anoikis-resistant MCF-7 and MDA-MB-231 breast cancer cell lines by inducing cell cycle arrest. ( Han, W; Kim, JB; Ko, E; Lee, KW; Noh, DY; Park, SY; Shin, I; Song, AK; Yu, JH, 2010) |
| "Berberine was added to MCF-7 cells in culture, and proliferation, side population (SP) cells and expression of ABCG2 were examined." | 1.35 | Berberine diminishes the side population and ABCG2 transporter expression in MCF-7 breast cancer cells. ( Han, W; Kim, JB; Ko, E; Noh, DY; Park, SY; Shin, I, 2008) |
| "Berberine was added to proliferating MCF-7 and MDA-MB-231 cells in culture." | 1.35 | Berberine inhibits growth of the breast cancer cell lines MCF-7 and MDA-MB-231. ( Bae, JY; Han, W; Kim, JB; Kim, S; Ko, E; Lee, JE; Lee, KM; Noh, DY; Shin, I, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (8.77) | 29.6817 |
| 2010's | 39 (68.42) | 24.3611 |
| 2020's | 13 (22.81) | 2.80 |
| Authors | Studies |
|---|---|
| Ziasarabi, P | 1 |
| Sahebkar, A | 1 |
| Ghasemi, F | 1 |
| Lindh, MG | 1 |
| Mattsson, G | 1 |
| Koyi, H | 1 |
| Johansson, MB | 1 |
| Razmi, R | 1 |
| Palm, A | 1 |
| Centorrino, F | 1 |
| Andlovic, B | 1 |
| Cossar, P | 1 |
| Brunsveld, L | 1 |
| Ottmann, C | 1 |
| Hayashi, S | 1 |
| Takenaka, M | 1 |
| Hosono, M | 1 |
| Kogure, H | 1 |
| Hasatani, K | 1 |
| Suda, T | 1 |
| Maruyama, H | 1 |
| Matsunaga, K | 1 |
| Ihara, H | 1 |
| Yoshio, T | 1 |
| Nagaike, K | 1 |
| Yamada, T | 1 |
| Yakushijin, T | 1 |
| Takagi, T | 1 |
| Tsumura, H | 1 |
| Kurita, A | 1 |
| Asai, S | 1 |
| Ito, Y | 1 |
| Kuwai, T | 1 |
| Hori, Y | 1 |
| Maetani, I | 1 |
| Ikezawa, K | 1 |
| Iwashita, T | 1 |
| Matsumoto, K | 1 |
| Fujisawa, T | 1 |
| Nishida, T | 1 |
| Mwesigwa, PJ | 1 |
| Jackson, NJ | 1 |
| Caron, AT | 1 |
| Kanji, F | 1 |
| Ackerman, JE | 1 |
| Webb, JR | 1 |
| Scott, VCS | 1 |
| Eilber, KS | 1 |
| Underhill, DM | 1 |
| Anger, JT | 1 |
| Ackerman, AL | 1 |
| Shi, LY | 1 |
| Subramanian, A | 1 |
| Weng, L | 1 |
| Lee, S | 1 |
| Kisslinger, K | 1 |
| Nam, CY | 1 |
| Ross, CA | 1 |
| Yang, M | 1 |
| Yang, C | 2 |
| Zhang, Y | 4 |
| Yan, X | 1 |
| Ma, Y | 1 |
| Cao, Y | 1 |
| Xu, Q | 1 |
| Tu, K | 1 |
| Zhang, M | 2 |
| Sato, Y | 1 |
| Wang, Y | 2 |
| Song, Y | 1 |
| Geng, W | 1 |
| Yan, S | 1 |
| Nakamura, K | 1 |
| Kikukawa, T | 1 |
| Demura, M | 1 |
| Ayabe, T | 1 |
| Aizawa, T | 1 |
| Tsuji, K | 1 |
| Matsuoka, YJ | 1 |
| Kuchiba, A | 1 |
| Suto, A | 1 |
| Ochi, E | 1 |
| Zhou, G | 1 |
| Yang, Y | 1 |
| Jing, B | 1 |
| Sun, B | 1 |
| Hu, S | 1 |
| Liu, Z | 1 |
| Thakurata, DG | 1 |
| Das, KC | 1 |
| Dhar, SS | 1 |
| Dian, L | 2 |
| Xu, Z | 1 |
| Sun, Y | 3 |
| Li, J | 5 |
| Lu, H | 1 |
| Zheng, M | 1 |
| Wang, J | 4 |
| Drobot, L | 1 |
| Horak, I | 1 |
| Tang, Q | 1 |
| Liang, B | 1 |
| Zhang, L | 2 |
| Li, X | 4 |
| Li, H | 1 |
| Jing, W | 1 |
| Jiang, Y | 1 |
| Zhou, F | 1 |
| Zhang, J | 5 |
| Meng, Y | 1 |
| Yang, X | 2 |
| Yang, H | 1 |
| Huang, G | 1 |
| Zhao, J | 1 |
| Cazzaniga, M | 2 |
| Zonzini, GB | 1 |
| Di Pierro, F | 1 |
| Moricoli, S | 1 |
| Bertuccioli, A | 1 |
| Meschi, M | 1 |
| Khorsandi, K | 1 |
| Kianmehr, Z | 1 |
| Li, XY | 2 |
| Shi, LX | 1 |
| Shi, NN | 1 |
| Chen, WW | 1 |
| Qu, XW | 1 |
| Li, QQ | 1 |
| Duan, XJ | 1 |
| Li, XT | 1 |
| Li, QS | 1 |
| Huang, B | 1 |
| Wen, G | 1 |
| Li, R | 1 |
| Wu, M | 1 |
| Zou, Z | 1 |
| Wang, W | 1 |
| Tong, Y | 1 |
| Zhao, L | 1 |
| Zhang, C | 2 |
| Ponnusamy, L | 1 |
| Kothandan, G | 1 |
| Manoharan, R | 1 |
| Ma, W | 2 |
| Yu, M | 1 |
| Wang, B | 1 |
| Xu, S | 1 |
| Ye, X | 1 |
| Zheng, X | 2 |
| Zhao, Y | 4 |
| Jia, Y | 1 |
| Shao, D | 2 |
| Zhang, F | 2 |
| Sun, M | 1 |
| Dawulieti, J | 1 |
| Hu, H | 1 |
| Cui, L | 1 |
| Pan, Y | 2 |
| Sun, W | 1 |
| Zhang, S | 1 |
| He, K | 2 |
| Du, J | 1 |
| Chen, L | 2 |
| Abrams, SL | 2 |
| Akula, SM | 1 |
| Meher, AK | 1 |
| Steelman, LS | 2 |
| Gizak, A | 1 |
| Duda, P | 1 |
| Rakus, D | 1 |
| Martelli, AM | 2 |
| Ratti, S | 1 |
| Cocco, L | 1 |
| Montalto, G | 2 |
| Cervello, M | 2 |
| Ruvolo, P | 1 |
| Libra, M | 2 |
| Falzone, L | 1 |
| Candido, S | 2 |
| McCubrey, JA | 2 |
| Tan, Y | 1 |
| Jing, Z | 2 |
| Lv, J | 2 |
| Zhang, Z | 1 |
| Lin, J | 1 |
| Cao, X | 1 |
| Zhao, Z | 2 |
| Liu, P | 1 |
| Mao, W | 3 |
| Lo, SN | 1 |
| Wang, CW | 1 |
| Chen, YS | 1 |
| Huang, CC | 1 |
| Wu, TS | 1 |
| Li, LA | 1 |
| Lee, IJ | 1 |
| Ueng, YF | 1 |
| Bonanni, B | 1 |
| Hashemi-Niasari, F | 1 |
| Rabbani-Chadegani, A | 1 |
| Razmi, M | 1 |
| Fallah, S | 1 |
| Pierpaoli, E | 2 |
| Fiorillo, G | 1 |
| Lombardi, P | 2 |
| Salvatore, C | 2 |
| Geroni, C | 2 |
| Piacenza, F | 1 |
| Provinciali, M | 2 |
| Jabbarzadeh Kaboli, P | 1 |
| Leong, MP | 1 |
| Ismail, P | 1 |
| Ling, KH | 1 |
| Tak, J | 1 |
| Sabarwal, A | 1 |
| Shyanti, RK | 1 |
| Singh, RP | 1 |
| Jin, H | 1 |
| Ko, YS | 1 |
| Park, SW | 1 |
| Chang, KC | 1 |
| Kim, HJ | 1 |
| Gao, X | 2 |
| Wu, P | 1 |
| Wink, M | 1 |
| Liang, Z | 1 |
| Li, M | 1 |
| Sun, C | 1 |
| Ji, J | 1 |
| Yang, W | 1 |
| Ma, X | 1 |
| Zhou, J | 1 |
| Zhang, CX | 1 |
| Li, N | 2 |
| Ju, RJ | 1 |
| Shi, JF | 1 |
| Sun, MG | 1 |
| Zhao, WY | 1 |
| Mu, LM | 1 |
| Yan, Y | 1 |
| Lu, WL | 1 |
| Wen, CJ | 1 |
| Wu, LX | 1 |
| Fu, LJ | 1 |
| Yu, J | 1 |
| Zhang, YW | 1 |
| Zhang, X | 1 |
| Zhou, HH | 1 |
| Kim, S | 5 |
| Oh, SJ | 1 |
| Lee, J | 2 |
| Han, J | 3 |
| Jeon, M | 1 |
| Jung, T | 1 |
| Lee, SK | 3 |
| Bae, SY | 1 |
| Kim, J | 3 |
| Gil, WH | 1 |
| Kim, SW | 1 |
| Lee, JE | 5 |
| Nam, SJ | 4 |
| Qiu, DM | 1 |
| Chen, SH | 1 |
| Cao, SP | 1 |
| Xia, XL | 1 |
| Jin, X | 1 |
| Yan, TH | 1 |
| Yan, L | 1 |
| Li, Q | 1 |
| Wang, RL | 1 |
| Hu, ZL | 1 |
| Jiang, YY | 1 |
| Sun, QY | 1 |
| Cao, YB | 1 |
| Tan, W | 1 |
| Tan, R | 1 |
| Zhong, Z | 1 |
| Suo, Z | 1 |
| Hu, X | 1 |
| Lee, KH | 1 |
| Lo, HL | 1 |
| Tang, WC | 1 |
| Hsiao, HH | 1 |
| Yang, PM | 1 |
| Zhao, SJ | 1 |
| Shi, HL | 1 |
| Qiu, SP | 1 |
| Xie, JQ | 1 |
| Wu, H | 1 |
| Zhang, BB | 1 |
| Wang, ZT | 1 |
| Yuan, JY | 1 |
| Wu, XJ | 1 |
| Xie, J | 1 |
| Xu, Y | 1 |
| Huang, X | 1 |
| Chen, Y | 1 |
| Fu, J | 1 |
| Xi, M | 1 |
| Wang, L | 1 |
| Damiani, E | 1 |
| Orlando, F | 1 |
| Lucarini, G | 1 |
| Bartozzi, B | 1 |
| Donati, A | 1 |
| Li, Y | 1 |
| Wang, K | 1 |
| Bao, J | 1 |
| Jia, X | 1 |
| Liang, Y | 1 |
| Wang, X | 2 |
| Chen, M | 1 |
| Su, H | 1 |
| Li, P | 1 |
| Wan, JB | 1 |
| He, C | 1 |
| Su, K | 1 |
| Hu, P | 1 |
| Kuang, C | 1 |
| Xiang, Q | 1 |
| Yang, F | 1 |
| Xiang, J | 1 |
| Zhu, S | 1 |
| Wei, L | 2 |
| Zhang, R | 1 |
| Qiao, H | 1 |
| Chen, S | 1 |
| Chen, X | 1 |
| Dou, K | 1 |
| Zhu, M | 1 |
| Zhang, D | 1 |
| Yang, L | 1 |
| Yang, T | 1 |
| Kim, JB | 4 |
| Ko, E | 3 |
| Han, W | 3 |
| Shin, I | 3 |
| Park, SY | 2 |
| Noh, DY | 3 |
| Choi, JH | 1 |
| Yang, JH | 1 |
| Kim, JH | 3 |
| Yu, JH | 1 |
| Lee, KW | 1 |
| Song, AK | 1 |
| Patil, JB | 1 |
| Jayaprakasha, GK | 1 |
| Kuo, HP | 2 |
| Chuang, TC | 2 |
| Yeh, MH | 1 |
| Hsu, SC | 2 |
| Way, TD | 1 |
| Chen, PY | 1 |
| Wang, SS | 1 |
| Chang, YH | 1 |
| Kao, MC | 2 |
| Liu, JY | 2 |
| Kim, NY | 1 |
| Cho, DH | 1 |
| Choi, MY | 2 |
| Kim, JS | 2 |
| Choe, JH | 2 |
| Pazhang, Y | 1 |
| Ahmadian, S | 1 |
| Javadifar, N | 1 |
| Shafiezadeh, M | 1 |
| Jung, SP | 1 |
| Chou, HC | 1 |
| Lu, YC | 1 |
| Cheng, CS | 1 |
| Chen, YW | 1 |
| Lyu, PC | 1 |
| Lin, CW | 1 |
| Timms, JF | 1 |
| Chan, HL | 1 |
| Wu, JB | 1 |
| Lei, F | 1 |
| Cui, XJ | 1 |
| He, Y | 1 |
| Hai, L | 1 |
| Wu, Y | 1 |
| Liu, Q | 1 |
| Yang, Q | 1 |
| Tsai, SC | 1 |
| Tseng, HH | 1 |
| Chen, YC | 1 |
| Kuo, CL | 1 |
| Kuo, YH | 1 |
| Zanardi, M | 1 |
| Quirico, E | 1 |
| Benvenuti, C | 1 |
| Pezzana, A | 1 |
| Chappell, WH | 1 |
| Franklin, RA | 1 |
| LaHair, MM | 1 |
| Nicoletti, F | 1 |
| Polesel, J | 1 |
| Talamini, R | 1 |
| Milella, M | 1 |
| Tafuri, A | 1 |
| Issat, T | 1 |
| Jakóbisiak, M | 1 |
| Golab, J | 1 |
| Lee, KM | 1 |
| Bae, JY | 1 |
| Iwasa, K | 1 |
| Moriyasu, M | 1 |
| Yamori, T | 1 |
| Turuo, T | 1 |
| Lee, DU | 1 |
| Wiegrebe, W | 1 |
1 review available for berberine and Breast Cancer
| Article | Year |
|---|---|
Relationship Between Metabolic Disorders and Breast Cancer Incidence and Outcomes. Is There a Preventive and Therapeutic Role for Berberine?
Topics: Berberine; Blood Glucose; Breast Neoplasms; Female; Humans; Incidence; Insulin Resistance; Metabolic | 2018 |
56 other studies available for berberine and Breast Cancer
| Article | Year |
|---|---|
Evaluation of the Effects of Nanomicellar Curcumin, Berberine, and Their Combination with 5-Fluorouracil on Breast Cancer Cells.
Topics: Apoptosis; Berberine; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Curcumin; Drug Synergi | 2021 |
Topics: Adult; Air Pollution; alpha-Defensins; Amino Acid Sequence; Animals; Bacteria; Berberine; Breast Neo | 2022 |
Berberine alkaloids inhibit the proliferation and metastasis of breast carcinoma cells involving Wnt/β-catenin signaling and EMT.
Topics: Berberine; Berberine Alkaloids; beta Catenin; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation | 2022 |
Enhanced CHOLESTEROL biosynthesis promotes breast cancer metastasis via modulating CCDC25 expression and neutrophil extracellular traps formation.
Topics: Animals; Berberine; Breast Neoplasms; Caveolin 1; Cholesterol; Extracellular Traps; Female; Histones | 2022 |
Gut Microbiota, Metabolic Disorders and Breast Cancer: Could Berberine Turn Out to Be a Transversal Nutraceutical Tool? A Narrative Analysis.
Topics: Berberine; Breast Neoplasms; Butyrates; Dysbiosis; Estrogens; Fatty Acids, Volatile; Female; Gastroi | 2022 |
The Effect of Berberine Follow by Blue Light Irradiation and Valproic Acid on the Growth Inhibition of MDA-MB-231 Breast Cancer Cells.
Topics: Apoptosis; Berberine; Breast Neoplasms; Cell Line, Tumor; Female; Humans; Photochemotherapy; Photose | 2023 |
Multiple stimulus-response berberine plus baicalin micelles with particle size-charge-release triple variable properties for breast cancer therapy.
Topics: Antineoplastic Agents; Berberine; Breast Neoplasms; Cell Line, Tumor; Drug Carriers; Female; Humans; | 2023 |
Integrated network pharmacology, bioinformatics, and molecular docking to explore the mechanisms of berberine regulating autophagy in breast cancer.
Topics: Autophagy; Berberine; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Computational Biolog | 2023 |
Berberine Inhibits Proliferative Ability of Breast Cancer Cells by Reducing Metadherin.
Topics: Adult; Apoptosis; Berberine; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; | 2019 |
Berberine Inhibits MDA-MB-231 Cells by Attenuating Their Inflammatory Responses.
Topics: Alkaloids; Antioxidants; Berberine; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Prolifer | 2020 |
Berberine and Emodin abrogates breast cancer growth and facilitates apoptosis through inactivation of SIK3-induced mTOR and Akt signaling pathway.
Topics: Apoptosis; Berberine; Blotting, Western; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Surviv | 2020 |
In-vitro and in-vivo anti-breast cancer activity of synergistic effect of berberine and exercise through promoting the apoptosis and immunomodulatory effects.
Topics: Animals; Antineoplastic Agents; Apoptosis; Berberine; Breast Neoplasms; Cell Line, Tumor; Cell Survi | 2020 |
Biomimetic co-assembled nanodrug of doxorubicin and berberine suppresses chemotherapy-exacerbated breast cancer metastasis.
Topics: Animals; Berberine; Biomimetics; Breast Neoplasms; Cell Line, Tumor; Doxorubicin; Humans; Lung Neopl | 2021 |
GSK-3β Can Regulate the Sensitivity of MIA-PaCa-2 Pancreatic and MCF-7 Breast Cancer Cells to Chemotherapeutic Drugs, Targeted Therapeutics and Nutraceuticals.
Topics: Adenocarcinoma; Adenylate Kinase; Antineoplastic Agents; bcl-X Protein; Berberine; Biphenyl Compound | 2021 |
Berberine Reverses Hypoxia-induced Chemoresistance in Breast Cancer through the Inhibition of AMPK- HIF-1α.
Topics: AMP-Activated Protein Kinases; Animals; Antineoplastic Agents; Berberine; Breast Neoplasms; Cell Hyp | 2017 |
Berberine activates caspase-9/cytochrome c-mediated apoptosis to suppress triple-negative breast cancer cells in vitro and in vivo.
Topics: Animals; Apoptosis; Berberine; Breast Neoplasms; Caspase 9; Cell Line, Tumor; Cytochromes c; Female; | 2017 |
Berberine Activates Aryl Hydrocarbon Receptor but Suppresses CYP1A1 Induction through miR-21-3p Stimulation in MCF-7 Breast Cancer Cells.
Topics: Basic Helix-Loop-Helix Transcription Factors; Berberine; Berberine Alkaloids; Breast Neoplasms; Cyto | 2017 |
Synergy of theophylline reduces necrotic effect of berberine, induces cell cycle arrest and PARP, HMGB1, Bcl-2 family mediated apoptosis in MDA-MB-231 breast cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2-Associated X Protein; Berberine; Br | 2018 |
Antitumor activity of NAX060: A novel semisynthetic berberine derivative in breast cancer cells.
Topics: Alkaloids; Apoptosis; Berberine; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; | 2018 |
Antitumor effects of berberine against EGFR, ERK1/2, P38 and AKT in MDA-MB231 and MCF-7 breast cancer cells using molecular modelling and in vitro study.
Topics: Antineoplastic Agents, Phytogenic; Berberine; Breast Neoplasms; Catalytic Domain; Enzyme Stability; | 2019 |
Berberine enhances posttranslational protein stability of p21/cip1 in breast cancer cells via down-regulation of Akt.
Topics: Berberine; Breast Neoplasms; Cyclin-Dependent Kinase Inhibitor p21; Down-Regulation; Female; Gene Ex | 2019 |
13-Ethylberberine Induces Apoptosis through the Mitochondria-Related Apoptotic Pathway in Radiotherapy-Resistant Breast Cancer Cells.
Topics: Apoptosis; Berberine; Breast Neoplasms; Cell Line, Tumor; Female; Gene Expression Regulation, Neopla | 2019 |
Jatrorrhizine inhibits mammary carcinoma cells by targeting TNIK mediated Wnt/β-catenin signalling and epithelial-mesenchymal transition (EMT).
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Berberine; beta Catenin; Breast Neoplasms; Ce | 2019 |
Berberine attenuates XRCC1-mediated base excision repair and sensitizes breast cancer cells to the chemotherapeutic drugs.
Topics: Antineoplastic Agents; Berberine; Breast Neoplasms; Camptothecin; Cell Cycle Checkpoints; Cell Line, | 2019 |
Modulation of drug-resistant membrane and apoptosis proteins of breast cancer stem cells by targeting berberine liposomes.
Topics: Animals; Apoptosis Regulatory Proteins; ATP-Binding Cassette Transporters; Berberine; Breast Neoplas | 2013 |
Genomic screening for targets regulated by berberine in breast cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Berberine; Biomarkers, Tumor; Breast Neoplasms; Cell Cycle; Cell P | 2013 |
Berberine suppresses TPA-induced fibronectin expression through the inhibition of VEGF secretion in breast cancer cells.
Topics: Berberine; Breast Neoplasms; Cell Line, Tumor; Female; Fibronectins; Humans; MCF-7 Cells; Phosphatid | 2013 |
Suppression of human breast cancer cell metastasis by coptisine in vitro.
Topics: Berberine; Breast Neoplasms; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cell Proliferation; Col | 2014 |
Design, synthesis, and anticancer activity of novel berberine derivatives prepared via CuAAC "click" chemistry as potential anticancer agents.
Topics: Antineoplastic Agents; Berberine; Breast Neoplasms; Cell Line, Tumor; Click Chemistry; Drug Design; | 2014 |
Berberine interfered with breast cancer cells metabolism, balancing energy homeostasis.
Topics: Antineoplastic Agents, Phytogenic; Berberine; Breast Neoplasms; Cell Line, Tumor; Energy Metabolism; | 2015 |
A gene expression signature-based approach reveals the mechanisms of action of the Chinese herbal medicine berberine.
Topics: AMP-Activated Protein Kinases; Apoptosis; Berberine; Biomarkers, Tumor; Blotting, Western; Breast Ne | 2014 |
Berberine hydrochloride IL-8 dependently inhibits invasion and IL-8-independently promotes cell apoptosis in MDA-MB-231 cells.
Topics: Apoptosis; Berberine; Breast Neoplasms; Cell Line, Tumor; Female; Gene Expression Regulation, Neopla | 2014 |
Berberine-induced apoptosis in human breast cancer cells is mediated by reactive oxygen species generation and mitochondrial-related apoptotic pathway.
Topics: Apoptosis; Berberine; Breast Neoplasms; Caspase 3; Cell Survival; Female; Humans; MCF-7 Cells; Membr | 2015 |
Antiangiogenic and antitumor activities of berberine derivative NAX014 compound in a transgenic murine model of HER2/neu-positive mammary carcinoma.
Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Berberine; Berberine Alkaloids; beta-Galactosidase; Bre | 2015 |
Berberine in combination with cisplatin suppresses breast cancer cell growth through induction of DNA breaks and caspase-3-dependent apoptosis.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Berberine; Breast; | 2016 |
Synergistic chemopreventive effects of curcumin and berberine on human breast cancer cells through induction of apoptosis and autophagic cell death.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Autophagy; Beclin-1; Berberine; Breast Neoplasms; Cell | 2016 |
Tumor suppressor berberine binds VASP to inhibit cell migration in basal-like breast cancer.
Topics: Actin Cytoskeleton; Animals; Antineoplastic Agents; Berberine; Breast Neoplasms; Cell Adhesion Molec | 2016 |
Berberine reverses lapatinib resistance of HER2-positive breast cancer cells by increasing the level of ROS.
Topics: Antineoplastic Combined Chemotherapy Protocols; Berberine; Breast Neoplasms; Cell Line, Tumor; Drug | 2016 |
Berberine inhibits the proliferation and migration of breast cancer ZR-75-30 cells by targeting Ephrin-B2.
Topics: Antineoplastic Agents, Phytogenic; Berberine; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell M | 2017 |
Berberine diminishes the side population and ABCG2 transporter expression in MCF-7 breast cancer cells.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette | 2008 |
Berberine suppresses TNF-alpha-induced MMP-9 and cell invasion through inhibition of AP-1 activity in MDA-MB-231 human breast cancer cells.
Topics: Berberine; Breast Neoplasms; Cell Line, Tumor; Enzyme Induction; Humans; Matrix Metalloproteinase 9; | 2008 |
The alkaloid Berberine inhibits the growth of Anoikis-resistant MCF-7 and MDA-MB-231 breast cancer cell lines by inducing cell cycle arrest.
Topics: Anoikis; Antineoplastic Agents, Phytogenic; Berberine; Breast Neoplasms; Cell Cycle; Cell Line, Tumo | 2010 |
Berberine induces apoptosis in breast cancer cells (MCF-7) through mitochondrial-dependent pathway.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Berberine; Blotting, Western; Breast Neoplasms; Caspas | 2010 |
Growth suppression of HER2-overexpressing breast cancer cells by berberine via modulation of the HER2/PI3K/Akt signaling pathway.
Topics: Berberine; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Female; Gene Exp | 2011 |
Effect of berberine on p53 expression by TPA in breast cancer cells.
Topics: Antineoplastic Agents; Berberine; Blotting, Western; Breast Neoplasms; Carcinogens; Cell Line, Tumor | 2012 |
COX-2 and survivin reduction may play a role in berberine-induced apoptosis in human ductal breast epithelial tumor cell line.
Topics: Antineoplastic Agents; Apoptosis; Aspirin; Berberine; Biomarkers, Tumor; Breast Neoplasms; Carcinoma | 2012 |
Berberine suppresses the TPA-induced MMP-1 and MMP-9 expressions through the inhibition of PKC-α in breast cancer cells.
Topics: Adenocarcinoma; Berberine; Breast Neoplasms; Carcinogens; Cell Line, Tumor; Cell Movement; Dose-Resp | 2012 |
Proteomic and redox-proteomic analysis of berberine-induced cytotoxicity in breast cancer cells.
Topics: Berberine; Breast Neoplasms; Cell Line, Tumor; Cytotoxins; Female; Humans; Neoplasm Proteins; Oxidat | 2012 |
Design, synthesis and multidrug resistance reversal activity evaluation of 8-oxocoptisine derivatives.
Topics: Antineoplastic Agents; Berberine; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Desig | 2012 |
Radiosensitization effects of berberine on human breast cancer cells.
Topics: Antigens, Nuclear; Berberine; Breast Neoplasms; Cell Survival; DNA Breaks, Double-Stranded; DNA-Bind | 2012 |
Berberine, an isoquinoline alkaloid, inhibits the metastatic potential of breast cancer cells via Akt pathway modulation.
Topics: Antineoplastic Agents, Phytogenic; Berberine; Breast Neoplasms; Cell Adhesion; Cell Line, Tumor; Cel | 2012 |
Use of a lipid-lowering food supplement in patients on hormone therapy following breast cancer.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Berberine; Biological Products; Breast Neopla | 2012 |
Ectopic NGAL expression can alter sensitivity of breast cancer cells to EGFR, Bcl-2, CaM-K inhibitors and the plant natural product berberine.
Topics: Acute-Phase Proteins; Antibiotics, Antineoplastic; Benzylamines; Berberine; Biphenyl Compounds; Brea | 2012 |
Berberine, a natural cholesterol reducing product, exerts antitumor cytostatic/cytotoxic effects independently from the mevalonate pathway.
Topics: Anticholesteremic Agents; Antineoplastic Agents; Berberine; Breast Neoplasms; Cell Line, Tumor; Cell | 2006 |
Berberine inhibits growth of the breast cancer cell lines MCF-7 and MDA-MB-231.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Berberine; Breast Neoplasms; Cell Cycle; Cell Line, Tu | 2008 |
In vitro cytotoxicity of the protoberberine-type alkaloids.
Topics: Animals; Antineoplastic Agents, Phytogenic; Berberine; Berberine Alkaloids; Brain Neoplasms; Breast | 2001 |